NEW DELHI : Raising hopes for a potential treatment of Covid-19, India’s premier research organization Council of Scientific and Industrial Research (CSIR) has decided to test its new drug against Sepsis to treat critical patients of Covid-19.
The drug has recently been approved for marketing in India and would be available commercially as Sepsivac® from Ahmedabad-based Cadila Pharmaceuticals Limited.
The pharmaceutical company was supported by CSIR laboratories led by Indian Institute of Integrative Medicine (IIIM), Jammu in development of this drug, which has also found effective for leprosy patients. “This is a moment of pride for all of us as, as it is the only such drug in the global market which has been approved to treat